Renal Cell Cancer Clinical Trial
Official title:
A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer
- Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1
and Flt3. Phase I study has shown that the toxicity is manageable.
- The purpose of this study is to compare the efficacy and safety profile between
Famitinib and Sunitinib in patients with metastatic renal cell carcinoma.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01392729 -
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)
|
N/A | |
Completed |
NCT00694096 -
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
|
Phase 1 | |
Completed |
NCT00520403 -
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
|
Phase 2 | |
Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
Completed |
NCT00172003 -
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
|
Phase 4 | |
Completed |
NCT02493751 -
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
|
Phase 1 | |
Recruiting |
NCT01967407 -
IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.
|
Phase 1/Phase 2 | |
Completed |
NCT00509704 -
Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
|
N/A | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04535921 -
Fear of Cancer Recurrence in Genitourinary Cancer
|
||
Recruiting |
NCT04620603 -
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01122615 -
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
|
Phase 1 | |
Completed |
NCT00979329 -
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
|
N/A | |
Active, not recruiting |
NCT02429440 -
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
|
Phase 1/Phase 2 | |
Recruiting |
NCT06362369 -
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02684006 -
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
|
Phase 3 | |
Completed |
NCT02375776 -
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
|
N/A | |
Completed |
NCT01598597 -
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
|
N/A | |
Completed |
NCT00465179 -
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT01158534 -
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
|
Phase 2 |